Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

Shots:Jeff spoke about the first patient enrolled in a P-II study of D-4517.2 for the treatment of wet AMD and DMEJeff also talked about Ashvatta’s Hydroxyl Dendrimer Platform and how this technology is beneficial to treat AMD and DMEThe interview gives a profound understanding of how Ashvattha is developing hydroxyl dendrimer therapeutics…